Table 4.
Dose reductions and discontinuations
| Cycle | No. of patients (%) | Dose reductions of carfilzomib | Dose reductions of pomalidomide | Dose discontinuations of pomalidomide or carfilzomib | ||
|---|---|---|---|---|---|---|
| n | Reason | n | Reason | |||
| 1 | 32 (100) | — | — | 1 | Febrile neutropenia | 4, includes 1 discontinuation due to an AE or SAE, 1 discontinuation due to patient’s death, and 1 withdrawal of consent |
| 2 | 28 (89) | — | — | 4 | Febrile neutropenia, rash, neutropenia, thrombocytopenia | 1 |
| 3 | 27 (84) | 1 | Pneumonia | 1 | Thrombocytopenia | 2, includes 1 discontinuation due to an AE or SAE |
| 4 | 25 (78) | — | — | 1 | Anemia | 4 |
| 5 | 21 (66) | 2 | Weight loss, shortness of breath | 1 | Neutropenia | 2 |
| 6 | 19 (59) | 1 | CHF | 1 | Car accident | 2, includes 1 discontinuation due to patient’s death |
| 7 | 17 (53) | — | — | — | — | 3, includes 1 withdrawal of consent |
| 8 | 15 (47) | — | — | — | — | 3, includes 1 discontinuation due to an AE or SAE and 1 withdrawal of consent |
| 9 | 12 (38) | — | — | — | — | 2 |
| 10 | 9 (28) | 1 | Neutropenia | — | — | 2 |
| 11 | 7 (22) | — | — | — | — | 2, includes 1 discontinuation due to patient’s death |
| 12 | 5 (16) | — | — | — | — | — |
| 13 | 5 (16) | 1 | Neutropenia | — | — | — |
| 14 | 5 (16) | — | — | — | — | 2 |
| 15 | 3 (9) | — | — | — | — | — |
| 16 | 3 (9) | — | — | — | — | — |
| 17 | 3 (9) | — | — | — | — | — |
| 18+ | 3 (9) | — | — | — | — | 3, includes 1 discontinuation due to an AE or SAE |
SAE, severe AE.
— indicates no reduction or discontinuation.